Eversept Partners LP Trims Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Eversept Partners LP decreased its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 23.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 996,102 shares of the biopharmaceutical company's stock after selling 297,155 shares during the quarter. Eversept Partners LP owned about 2.03% of Puma Biotechnology worth $3,038,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of Puma Biotechnology by 17.0% in the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company's stock valued at $1,534,000 after buying an additional 87,504 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Puma Biotechnology by 103.9% during the third quarter. Jane Street Group LLC now owns 32,129 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 16,374 shares during the last quarter. Barclays PLC boosted its holdings in shares of Puma Biotechnology by 146.5% during the third quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company's stock worth $199,000 after purchasing an additional 46,370 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Puma Biotechnology in the third quarter valued at $68,000. Finally, Franklin Resources Inc. acquired a new position in Puma Biotechnology in the third quarter valued at $41,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PBYI has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Friday, February 28th. StockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday.

Puma Biotechnology Trading Down 0.3 %

PBYI traded down $0.01 during trading on Friday, hitting $3.00. 164,147 shares of the company's stock were exchanged, compared to its average volume of 440,800. The stock has a 50 day moving average price of $3.11 and a 200 day moving average price of $3.02. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $5.26. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The firm has a market cap of $148.83 million, a P/E ratio of 6.25 and a beta of 1.34.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.29. The firm had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. As a group, analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.